EGFR and neoplasm: Although early tumor shrinkage and depth of response were shown to be strongly associated with survival outcomes, irrespective of the type of targeted therapy used or the primary tumor location, the findings were particularly pronounced in patients treated with chemotherapy plus an anti-EGFR antibody.